Targeting the ERG Oncogene with Splice-Switching Oligonucleotides as a Novel Therapeutic Strategy in Prostate Cancer

In VCaP prostate cancer cells, both splice-switching oligonucleotides were effective at inducing exon 4 skipping, which resulted in a reduction of overall ERG protein levels up to 96 hours following a single transfection.
[British Journal of Cancer]
Li, L., Hobson, L., Perry, L., Clark, B., Heavey, S., Haider, A., Sridhar, A., Shaw, G., Kelly, J., Freeman, A., Wilson, I., Whitaker, H., Nurmemmedov, E., Oltean, S., Porazinski, S., & Ladomery, M. (2020). Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer. British Journal of Cancer, 1–9. https://doi.org/10.1038/s41416-020-0951-2 Cite
Abstract
Bookmark

No account yet? Register

Share

E2F7, Regulated by miR‑30c, Inhibits Apoptosis and Promotes Cell Cycle of Prostate Cancer Cells

Transfection of miR‑30c mimicked into prostate cancer cells resulted in reduced cell viability, increased proportion of cells in the G1 phase and higher apoptotic rates.
[Oncology Reports]
Wang, Y., Pei, X., Xu, P., Tan, Z., Zhu, Z., Zhang, G., Jiang, Z., & Deng, Z. (2020). E2F7, regulated by miR‑30c, inhibits apoptosis and promotes cell cycle of prostate cancer cells. Oncology Reports. https://doi.org/10.3892/or.2020.7659 Cite
Abstract
Bookmark

No account yet? Register

Share

An Anti-PSMA Immunotoxin Reduces Mcl-1 and Bcl2A1 and Specifically Induces in Combination with the BAD-Like BH3 Mimetic ABT-737 Apoptosis in Prostate Cancer Cells

Combination with the BAD-like mimetic ABT-737 was examined on prostate cancer cells and 3D spheroids and in view of tumor growth and survival in the prostate cancer SCID mouse xenograft model.
[Cancers]
Cancers | Free Full-Text | An Anti-PSMA Immunotoxin Reduces Mcl-1 and Bcl2A1 and Specifically Induces in Combination with the BAD-Like BH3 Mimetic ABT-737 Apoptosis in Prostate Cancer Cells | HTML. (n.d.). Retrieved June 26, 2020, from https://www.mdpi.com/2072-6694/12/6/1648/htm Cite
Full Article
Bookmark

No account yet? Register

Share

The CHK1 Inhibitor MU380 Significantly Increases the Sensitivity of Human Docetaxel-Resistant Prostate Cancer Cells to Gemcitabine through the Induction of Mitotic Catastrophe

Both CHK1 inhibitors significantly potentiated the sensitivity to gemcitabine in a panel of chemo‐naïve and matched docetaxel‐resistant prostate cancer cell lines under 2D conditions.
[Molecular Oncology]
Drápela, S., Khirsariya, P., Weerden, W. M. van, Fedr, R., Suchánková, T., Búzová, D., Červený, J., Hampl, A., Puhr, M., Watson, W. R., Culig, Z., Krejčí, L., Paruch, K., & Souček, K. (n.d.). The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe. Molecular Oncology, n/a(n/a). https://doi.org/10.1002/1878-0261.12756 Cite
Abstract
Bookmark

No account yet? Register

Share

AR Phosphorylation and CHK2 Kinase Activity Regulates IR Stabilized AR-CHK2 Interaction and Prostate Cancer Survival

The destabilization of androgen receptor-checkpoint kinase 2 (CHK2) interactions induced by CHK2 variants impaired CHK2 negative regulation of cell growth.
[eLife]
Ta, H. Q., Dworak, N., Ivey, M. L., Roller, D. G., & Gioeli, D. (2020). AR phosphorylation and CHK2 kinase activity regulates IR stabilized AR-CHK2 interaction and prostate cancer survival. ELife, 9, e51378. https://doi.org/10.7554/eLife.51378 Cite
Abstract
Bookmark

No account yet? Register

Share

NIH’s New Sexual-Harassment Rules Are Still Too Weak, Say Critics

On 24 June, the US National Institutes of Health (NIH) described the actions it will take when alerted to reports of unsafe behavior, including restricting scientists from peer-review panels, holding back pending grants and refusing university requests to transfer funding to other institutions in cases where a harasser changes jobs.
[Nature News]
Press Release
Bookmark

No account yet? Register

Share

Gender Gap in Research Output Widens during Pandemic

A series of recent studies has demonstrated a significant drop in the productivity of female scientists, especially those early in their careers, relative to their male peers—and the gender gap is particularly pronounced for COVID-19 researchers.
[The Scientist]
Press Release
Bookmark

No account yet? Register

Share

Graduate Programs Drop GRE after Online Version Raises Concerns about Fairness

Scores of academics have raised concerns about the equity of the online version of the test, arguing it disadvantages prospective students from rural and low-income backgrounds. “If I were … a student trying to take this exam, satisfying [the online testing] criteria would be extremely difficult for me,” says Emily Levesque, an assistant professor of astronomy at the University of Washington, Seattle.
[ScienceInsider]
Press Release
Bookmark

No account yet? Register

Share

COVID-19 Cancels Charity Galas and Walks. Science Is Paying the Price

Foundations that fund biomedical research in the United States, the United Kingdom, and elsewhere are reporting record revenue drops because of the pandemic. One major factor: It has forced them to cancel key fundraising events, including glitzy galas, sponsored walks, Broadway partnerships, and more.
[ScienceInsider]
Press Release
Bookmark

No account yet? Register

Share

Virtual Lab Tours for Recruitment and Outreach

Virtual lab tours are not new, but they have never been as common as in-person lab tours. However, the pandemic has generated strong incentives for formerly in-person lab tours to go online.
[The Scientist]
Press Release
Bookmark

No account yet? Register

Share

Trump to Suspend New Visas for Foreign Scholars

With a proclamation issued on Monday, US President Donald Trump extended and expanded immigration restrictions to limit the entry of foreign workers to the United States. The move set off ripples of alarm among scientists and drew fire from experts concerned about the future of US science.
[Nature News]
Press Release
Bookmark

No account yet? Register

Share
Share